Uzma Zaidi (@uzmazaidi19) 's Twitter Profile
Uzma Zaidi

@uzmazaidi19

MBBS, FCPS
Bone Marrow Transplant Physician,
Section head, Myeloproliferative Neoplasms,
National Institute of Blood Diseases & Bone Marrow Transplantation

ID: 1135584201233883137

calendar_today03-06-2019 16:29:06

26 Tweet

112 Takipçi

174 Takip Edilen

Ruben A. Mesa, MD (@mpdrc) 's Twitter Profile Photo

Awesome Ann! Almost 600 registered!! It should be a great discussion of advances in MPNs - organized from TX but meant for the global MPN Community! Still time to register for free!! Naveen Pemmaraju, MD @UTHealthSAMDA @LeukemiaMDA

Blooducation (@blooducation) 's Twitter Profile Photo

Hi all! Our latest #blooducation podcast is live. Listen to Helen quiz Hayder Hussein on updates in #Essentialthrombocythaemia available on iTunes/Spotify or listen here: blooducation.co.uk/portfolio/curr…

Hi all! Our latest #blooducation podcast is live. Listen to Helen quiz <a href="/h4yder/">Hayder Hussein</a> on updates in #Essentialthrombocythaemia available on iTunes/Spotify or listen here: blooducation.co.uk/portfolio/curr…
The ASCO Post (@ascopost) 's Twitter Profile Photo

Hematologist and Bone Marrow Transplant Pioneer, Tahir Shamsi, MBBS, MRCPath, FRCPath, Dies at 59 ascopost.com/issues/februar…

Hematologist and Bone Marrow Transplant Pioneer, Tahir Shamsi, MBBS, MRCPath, FRCPath, Dies at 59 ascopost.com/issues/februar…
Hagop Kantarjian,MD (@drhkantarjian) 's Twitter Profile Photo

Non-Chemo regimen of venetoclax + gilteritinib highly active in R/R FLT3+ AML (including exposed to prior FLT3 inhibitors). Published now Journal of Clinical Oncology ascopubs.org/doi/full/10.12… #leusm #AML

Non-Chemo regimen of venetoclax + gilteritinib highly active in R/R FLT3+ AML (including exposed to prior FLT3 inhibitors). Published now <a href="/JCO_ASCO/">Journal of Clinical Oncology</a>  ascopubs.org/doi/full/10.12… #leusm #AML